Warning letter
Cytogen Corporation: warning letter of Sep 22, 1999
FDA warning letter UCM067698 · Center for Biologics Evaluation and Research
Key facts
| Reference number | UCM067698 |
|---|---|
| Company | Cytogen Corporation |
| Subject | OncoScint & ProstaScint |
| Issue date | Sep 22, 1999 |
| Posted date | Sep 22, 1999 |
| Issuing office | Center for Biologics Evaluation and Research |
| Product type | Biologics |
| CFR sections cited | 211.204, 2, 21, 211, 211.22, 211.42, 211.100, 211.165, 211.22(d), 211.165(a), 211.67(b), 211.192 and 1 more |
| Country | 3 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: